S
Stanley B. Kaye
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 128
Citations - 9177
Stanley B. Kaye is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 43, co-authored 128 publications receiving 8691 citations. Previous affiliations of Stanley B. Kaye include Cancer Research UK & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Fadlo R. Khuri,John Nemunaitis,Ian Ganly,James Arseneau,Ian F. Tannock,Larry Romel,Martin Gore,J. Ironside,Robert Hugh MacDougall,Carla Heise,Britta Randlev,Ann M. Gillenwater,Patricia A. Bruso,Stanley B. Kaye,Waun Ki Hong,David H. Kirn +15 more
TL;DR: A phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck found substantial objective responses, including a high proportion of complete responses.
Journal Article
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
TL;DR: DAC could have a role in increasing the efficacy of chemotherapy for patients whose tumors lack MLH1 expression because of hMLH1 promoter methylation, and is consistent with loss of MMR having no effect on sensitivity in vitro to Taxol.
Journal ArticleDOI
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
Udai Banerji,Anne O'Donnell,Michelle Scurr,Simon Pacey,Sarah Stapleton,Yasmin Asad,Laura Simmons,Alison Maloney,Florence I. Raynaud,Maeli Campbell,Michael I. Walton,Sunil R. Lakhani,Stanley B. Kaye,Paul Workman,Ian Judson +14 more
TL;DR: It has been possible to demonstrate that 17-AAG exhibits a tolerable toxicity profile with therapeutic plasma concentrations and target inhibition for 24 hours after treatment and some indications of clinical activity at the dose level 450 mg/m(2)/week.
Journal Article
A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
Ian Ganly,Ian Ganly,David H. Kirn,Susan G. Eckhardt,Gail I. Rodriguez,David S. Soutar,Randol Otto,Andrew G. Robertson,Oirhigh Park,Mark L. Gulley,Mark L. Gulley,Carla Heise,Daniel D. Von Hoff,Stanley B. Kaye +13 more
TL;DR: Preliminary results show that intratumoral administration of Onyx-015 is feasible, well tolerated, and associated with biological activity.
Journal ArticleDOI
"BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
David S.P. Tan,Christian Rothermundt,Karen Thomas,Elizabeth Bancroft,Rosalind A. Eeles,Susan Shanley,Audrey Ardern-Jones,Andrew R. Norman,Stanley B. Kaye,Martin Gore +9 more
TL;DR: There exists a clinical syndrome of BRCAness that includes serous histology, high response rates to first and subsequent lines of platinum-based treatment, longer TFIs between relapses, and improved OS.